Image

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Investigating Treatment Options for High-Risk Neuroblastoma in Young Patients

Recruiting
1-30 years
All
Phase N/A
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates the use of investigational medications along with standard therapy in treating young patients with high-risk neuroblastoma or ganglioneuroblastoma. Neuroblastoma is a type of cancer that occurs in certain types of nerve tissue and is most commonly found in children. The study aims to see if adding investigational medications can improve outcomes for these patients.

Participants in this study will receive either iobenguane I-131 or crizotinib in addition to standard cancer treatments. Iobenguane I-131 is a type of radiopharmaceutical therapy, while crizotinib targets specific genetic changes in the tumor. The study will compare how these treatments affect the progression of the disease and the overall survival of the patients.

  • Who can participate: Eligible participants are young patients diagnosed with neuroblastoma or ganglioneuroblastoma confirmed by pathology or specific tests. They must have no contraindications to certain medical procedures and agree to use effective contraception if of reproductive potential.
  • Study details: Participants will receive either iobenguane I-131 or crizotinib along with standard therapy. A placebo is not used in this study.
Print
Study details
    ganglioneuroblastoma
    neuroblastoma

TX8857

19 February 2024

Contact a study center
Step 1 Get in touch with the nearest study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Please provide your preferred way of contact1234
Other language

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.